Home » Stocks » MRK

Merck & Co., Inc. (MRK)

Stock Price: $76.27 USD 0.13 (0.17%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $76.28 +0.01 (0.01%) Jun 11, 7:59 PM
Market Cap 193.12B
Revenue (ttm) 48.02B
Net Income (ttm) 7.03B
Shares Out 2.53B
EPS (ttm) 2.77
PE Ratio 27.54
Forward PE 12.06
Dividend $2.48
Dividend Yield 3.25%
Trading Day June 11
Last Price $76.27
Previous Close $76.14
Change ($) 0.13
Change (%) 0.17%
Day's Open 76.58
Day's Range 75.60 - 76.86
Day's Volume 13,928,356
52-Week Range 15.32 - 85.73


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Final Trades: Allscripts, Kinder Morgan, Merck & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: KMI, MDRX
2 days ago - CNBC Television

It is hard to believe, but in just over three weeks the second quarter will come to a close and many investors will be reviewing their portfolios and making changes for the second half of 2021.

Other stocks mentioned: CVX, DOW, IBM, KO
2 days ago - 24/7 Wall Street

Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.

3 days ago - Zacks Investment Research

Attractive dividends plus strong growth? Yes, please.

Other stocks mentioned: GSK, VTRS
3 days ago - The Motley Fool

The U.S. government will pay $1.2 billion for 1.7 billion doses of Merck's experimental oral COVID-19 drug.

4 days ago - The Motley Fool

Merck & Co Inc (NYSE: MRK) has entered into a procurement agreement with the U.S. government for molnupiravir (MK-4482), an antiviral candidate for mild to moderate COVID-19. Molnupiravir is currently b...

4 days ago - Benzinga

Not only has Heska stock doubled in a year, it has quintupled over the past five years, and it's a 20-bagger over the last decade. Why is this animal health stock flying so high?

Other stocks mentioned: HSKA, IDXX, ISRG, NNOX, PFE, ZTS
4 days ago - The Motley Fool

Merck to supply U.S. government with oral antiviral drug used to treat Covid

YouTube video

Merck will supply an oral antiviral medication intended to treat mild to moderate Covid-19 to the U.S. government in a new procurement agreement. CNBC's Meg Tirrell reports.

4 days ago - CNBC Television

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Supply Agreement with U.S. Government for Molnupiravir

4 days ago - Business Wire

In the latest trading session, Merck (MRK) closed at $72.80, marking a -1.77% move from the previous day.

6 days ago - Zacks Investment Research

MADISON, N.J.--(BUSINESS WIRE)--MSD Animal Health to Acquire Assets of LIC Automation Ltd.

6 days ago - Business Wire

Merck & Co Inc (NYSE: MRK) has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab) plus Lenvima from Eisai Co Ltd (OTC: ESAL...

6 days ago - Benzinga

KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New Data on KEYTRUDA® Plus LENVIMA® Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

6 days ago - Business Wire

AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating Lynparza (olaparib) in a subset of early breast cance...

Other stocks mentioned: AZN
1 week ago - Benzinga

Merck & Co (NYSE: MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment in a subset of patients with renal cell carcinoma ...

1 week ago - Benzinga

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Given After Surgery Reduced Risk of Disease Recurrence or Death 32% vs Placebo as Adj Therapy in Patients with Renal Cell Carcinoma

1 week ago - Business Wire

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA Reduced Risk of Invasive Disease Recurrence or Death 42% vs Placebo in Adj Treatment of BRCA Mutated HER2-Neg Early Breast Cancer

1 week ago - Business Wire

In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women's health business into a standalone spinoff. As of Thursday, that sp...

1 week ago - Benzinga

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #merck--Merck Announces Completion of Organon & Co. Spinoff

1 week ago - Business Wire

The Merck spinoff Organon will likely do quite well. OGN stock is likely to be worth $52.77, or 48% above the when-issued price right now.

1 week ago - InvestorPlace

With solid fundamental metrics, these defensive stocks deserve your attention now The post 7 Best Stocks To Buy To Hedge Against A Potential Downturn appeared first on InvestorPlace. More From InvestorP...

Other stocks mentioned: CHWY, FCX, FSTA, IWD, PG, VIG
1 week ago - InvestorPlace

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA Germany (OTC: MKGAF). The payment is related ...

Other stocks mentioned: STRO
1 week ago - Benzinga

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors. The tri...

Other stocks mentioned: IMMP
1 week ago - Benzinga

KENILWORTH, N.J. & BRIDGEWATER, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Sanofi's First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States

1 week ago - Business Wire

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

1 week ago - Zacks Investment Research

A first-of-its-kind medical device from a top-10 biotech could change medical cannabis consumption.

Other stocks mentioned: CGC, CURLF, SAGE, TRSSF
1 week ago - The Motley Fool

NEW YORK, May 27, 2021 /PRNewswire/ -- Organon & Co. (NYSE: OGN) will be added to the S&P 500 prior to the open of trading on Thursday, June 3, replacing HollyFrontier, which will be removed from the S&...

Other stocks mentioned: LCI, OGN, SPGI
2 weeks ago - PRNewsWire

Warren Buffett is a legendary investor, but he's wrong to pare down these top-tier stocks.

Other stocks mentioned: ABBV, BMY, GM, SIRI
2 weeks ago - The Motley Fool

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2021 Dividend

2 weeks ago - Business Wire

The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.

2 weeks ago - Zacks Investment Research

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval for Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab...

2 weeks ago - Benzinga

When the operating income margin keeps on expanding, it means that the company is maintaining the costs of goods sold and other operating expenses under predetermined limits while net sales are growing.

Other stocks mentioned: ABT, NFLX
2 weeks ago - GuruFocus

TOTAL (TOT) signs a 10-year deal with Merck to sell clean energy to the latter. TOTAL is working to scale up renewable energy generation capability by adding new wind and solar assets.

2 weeks ago - Zacks Investment Research

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer

2 weeks ago - Business Wire

The Oracle of Omaha likely hasn't lost a minute of sleep over these stocks.

Other stocks mentioned: SNOW, STNE
3 weeks ago - The Motley Fool

Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.

3 weeks ago - Zacks Investment Research

Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in pancreatic cancer. Data w...

Other stocks mentioned: ONCY
3 weeks ago - Benzinga

With the trading day almost halfway over, the markets had made a handy recovery on Thursday, bouncing off the lows of last week.

Other stocks mentioned: MU, NVDA
3 weeks ago - 24/7 Wall Street

Merck & Co Inc's (NYSE: MRK) investigational 15-valent pneumococcal conjugate vaccine, V114, has met its primary immunogenicity and safety endpoints in two Phase 3 pediatric programs. Full results from ...

3 weeks ago - Benzinga

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results Phase 3 Pediatric Studies for V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine

3 weeks ago - Business Wire

Older investors typically rely on income-producing investments to fund their golden years. These prospects offer a healthy balance of dividends, growth, and reliability.

Other stocks mentioned: DUK, KO
3 weeks ago - The Motley Fool

Warren Buffett's Berkshire Hathaway cut back on financial, energy and drug stocks but beefed up his grocery and wireless holdings while adding an insurer.

Other stocks mentioned: BRK.A, BRK.B, BMY, CVX, WFC
3 weeks ago - Fox Business

Pharmaceutical stocks may come under increased pressure thanks to corporate tax increases proposed by President Joe Biden. This comes on top of the threat of federal drug price controls, according to an...

Other stocks mentioned: JNJ, PFE
3 weeks ago - GuruFocus

Berkshire Hathaway cuts stakes in Wells Fargo, Chevron and Merck

YouTube video

CNBC's Leslie Picker reports on some big moves Berkshire Hathaway made this past quarter.

Other stocks mentioned: BRK.A, BRK.B, CVX, WFC
3 weeks ago - CNBC Television

WASHINGTON and KENILWORTH, N.J., May 17, 2021 /PRNewswire/ -- Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launc...

3 weeks ago - PRNewsWire

Even the Oracle of Omaha is staring at some unrealized losses in his investment portfolio.

Other stocks mentioned: TEVA, VZ, VZA
4 weeks ago - The Motley Fool

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

4 weeks ago - Zacks Investment Research

Physiomics PLC (LON:PYC) jumped 11% to 6.65p in the early afternoon on the back of a further contract with German giant Merck. The consultancy said this contract is additional to the initial tranche of ...

4 weeks ago - Proactive Investors

These two companies should be on your radar.

Other stocks mentioned: BMY
4 weeks ago - The Motley Fool

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With Early-Stage Triple-Negative Breast Cancer

1 month ago - Business Wire

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as we... [Read more...]

Drug Manufacturers-General
Kenneth Frazier
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, Merck's revenue was $47.99 billion, an increase of 2.46% compared to the previous year's $46.84 billion. Earnings were $7.07 billion, a decrease of -28.20%.

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for Merck stock is "Buy." The 12-month stock price forecast is 92.89, which is an increase of 21.79% from the latest price.

Price Target
(21.79% upside)
Analyst Consensus: Buy